Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor

NCT03129945 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine the best medication to stop preterm labor. Recent studies have identify nifedipine and indomethacin as the two medications that are most likely to delay delivery for 48 hours, decrease maternal side effects and decrease some complications related to preterm delivery to the neonate. Both of these medications are commonly used to stop pre-term labor, therefore it has become our institution's standard to use these two medications in the setting of preterm labor. There have been limited studies comparing these two medications directly.

A total of 450 participants will be asked to participate across all study sites.

Conditions

  • Obstetric Labor, Premature

Interventions

DRUG

Nifedipine

Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.

DRUG

Indomethacin

Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.

Sponsors & Collaborators

Principal Investigators

  • Deborah A Wing, MD · University of California, Irvine

  • Mary Norton, MD · University of California, San Francisco

  • Gladys (Sandy) Ramos, MD · University of California, San Diego

  • Aisling Murphy, MD · University of California, Los Angeles

  • Veronique Tache, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2019-04-18
Completion
2019-04-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129945 on ClinicalTrials.gov